Cargando…

Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy

Human Immunodeficiency Virus Type 1 (HIV-1) protease inhibitors (PIs) are the most potent class of drugs in antiretroviral therapies. However, viral drug resistance to PIs could emerge rapidly thus reducing the effectiveness of those drugs. Of note, all current FDA-approved PIs are competitive inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hailiu, Nkeze, Joseph, Zhao, Richard Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490751/ https://www.ncbi.nlm.nih.gov/pubmed/22971934 http://dx.doi.org/10.1186/2045-3701-2-32

Ejemplares similares

Molecular characterization of HIV-1 genome in fission yeast Schizosaccharomyces pombe
por: Nkeze, Joseph, et al.
Publicado: (2015)

Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis
por: Mata-Munguía, Carlos, et al.
Publicado: (2014)

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration
por: Kantor, Rami, et al.
Publicado: (2005)

Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study
por: Nalwanga, Damalie, et al.
Publicado: (2021)

HIV-1 protease inhibition potential of functionalized polyoxometalates
por: Flütsch, Andreas, et al.
Publicado: (2011)

Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal
por: Kuehnemann, Chisaka, et al.
Publicado: (2022)

Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants.
por: Goldstein, P J, et al.
Publicado: (2000)

Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial
por: Soliman, Elsayed Z, et al.
Publicado: (2013)

Cellular Targets of HIV-1 Protease: Just the Tip of the Iceberg?
por: Centazzo, Matteo, et al.
Publicado: (2023)

Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 Infection
por: Firnhaber, Cynthia, et al.
Publicado: (2011)

Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment
por: Frohoff, Cordula, et al.
Publicado: (2011)

Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy
por: Winston, Alan, et al.
Publicado: (2013)

Improving Drug Sensitivity of HIV-1 Protease Inhibitors by Restriction of Cellular Efflux System in a Fission Yeast Model
por: Zhang, Jiantao, et al.
Publicado: (2022)

Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy
por: Cillo, Anthony R., et al.
Publicado: (2014)

Antiretroviral therapy and changing patterns of HIV stigmatisation in Entebbe, Uganda
por: Russell, Steve, et al.
Publicado: (2016)

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch
por: Eche, Simeon, et al.
Publicado: (2021)

Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration
por: Watanabe, Dai, et al.
Publicado: (2011)

Changes in functional connectivity in people with HIV switching antiretroviral therapy
por: Toniolo, Sofia, et al.
Publicado: (2020)

HIV-1 Protease in the Fission Yeast Schizosaccharomyces pombe
por: Benko, Zsigmond, et al.
Publicado: (2016)

Enfuvirtide antiretroviral therapy in HIV-1 infection
por: Kitchen, Christina MR, et al.
Publicado: (2008)

Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy
por: Chiu, Chris Y., et al.
Publicado: (2023)

The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets
por: Hartman, Tracy L., et al.
Publicado: (2012)

Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy
por: Zhao, Yan, et al.
Publicado: (2015)

Outcomes of protease inhibitor-based antiretroviral therapy amongst children and associated-factors in Yaoundé, Cameroon
por: Njom Nlend, Anne Esther, et al.
Publicado: (2019)

Free HIV Antiretroviral Therapy Enhances Adherence among Individuals on Stable Treatment: Implications for Potential Shortfalls in Free Antiretroviral Therapy
por: Byakika-Tusiime, Jayne, et al.
Publicado: (2013)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
por: Musana, Hellen, et al.
Publicado: (2021)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy
por: Martinez-Skinner, Andrea L., et al.
Publicado: (2015)

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands
por: Hubben, Gijs AA, et al.
Publicado: (2007)

No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy
por: Falcon-Neyra, Lola, et al.
Publicado: (2015)

A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy
por: Araínga, Mariluz, et al.
Publicado: (2017)

HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy
por: Kemp, Steven A., et al.
Publicado: (2022)

Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa
por: Rossouw, Theresa M., et al.
Publicado: (2015)

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
por: Yin, Dwight E., et al.
Publicado: (2020)

Allopregnanolone and neuroHIV: Potential benefits of neuroendocrine modulation in the era of antiretroviral therapy
por: Salahuddin, Mohammed F., et al.
Publicado: (2021)

Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals
por: Arruda, Mônica Barcellos, et al.
Publicado: (2016)

Persistent HIV-1 replication during antiretroviral therapy
por: Martinez-Picado, Javier, et al.
Publicado: (2016)

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy
por: Pérez-Valero, Ignacio, et al.
Publicado: (2013)

HIV and urethritis: time required for antiretroviral therapy to suppress HIV in semen
por: Matoga, Mitch, et al.
Publicado: (2023)

Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
por: Pasternak, Alexander O., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_m8g7bg2b4f5n46lb667iacn4ko